Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer

Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer

Abstract Purpose We conducted a retrospective analysis of the data of patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) to investigate the associations between clinical factors and the overall survival. Methods We retrieved the patient data from the medi...

Full description

Bibliographic Details
Main Authors: Minehiko Inomata, Masahiro Matsumoto, Isami Mizushima, Kana Hayashi, Zenta Seto, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe
Format: Article
Language:English
Published: SpringerOpen 2022-03-01
Series:The Egyptian Journal of Bronchology
Subjects:
Epidermal growth factor receptor
Tyrosine kinase inhibitor
Lung cancer
Osimertinib
Survival
Prognosis
Online Access:https://doi.org/10.1186/s43168-022-00121-1

Internet

https://doi.org/10.1186/s43168-022-00121-1

Similar Items